TY - JOUR
T1 - Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity
AU - Shimada, Y.
AU - Watanabe, G.
AU - Yamasaki, S.
AU - Maeda, M.
AU - Kawabe, A.
AU - Kaganoi, J. I.
AU - Itami, A.
AU - Fukumoto, M.
AU - Kanda, Y.
AU - Imamura, M.
N1 - Funding Information:
The authors thank Professor Hirohiko Yamabe, Kyoto University, for kindly preparing the paraffin section. The authors would also like to thank Ms Sandra Snider for her support in proofreading the manuscript and Shunzou Maetani, M.D, Ph.D, Vice president of Research Center of Tenri Hospital, for his excellent advice in statistical analysis. This work was supported in part by a Grant-in-Aid from the Japanese Ministry of Education, Science and Culture (Grant 09671301 and 09470265).
PY - 2000/5
Y1 - 2000/5
N2 - The aim of this study was to evaluate whether cisplatin sensitivity relates to patient's prognosis in oesophageal squamous cell carcinoma and to find a useful chemosensitivity molecular marker. 59 oesophageal squamous cell carcinoma (SCC) patients received cisplatin 30 mg/m2/week treatment of two to five cycles, followed by oesophagectomy. We analysed retrospectively whether the histological effect was related to patient's prognosis. Furthermore, to evaluate the relationship between the effect of preoperative cisplatin treatment and p53 and cyclin D1 expression, we investigated p53 and cyclin D1 expression in pretreatment biopsy samples using an immunohistochemical analysis and compared the results with the histological effect to cisplatin in the resected oesophagus. The cases that showed immunohistochemical p53 staining in the pretreatment biopsy samples were resistant to cisplatin (P=0.032). However, there was no relationship between cyclin D1 expression and histological effect (P=0.230). Nevertheless, combined analysis of p53 and cyclin D1 can predict histological effect (P=0.032). The prognosis of cisplatin-sensitive cases was significantly better than that of cisplatin-resistant cases (P=0.041). Cox's multivariate analysis revealed that the histological effect was an independent prognostic factor. In contrast, p53 protein accumulation and cyclin D1 were not. Histological response after neoadjuvant cisplatin treatment is a prognostic factor for oesophageal SCC and cisplatin chemotherapy may be selected according to the findings of p53 and cyclin D1 expression. Copyright (C) 2000 Elsevier Science Ltd.
AB - The aim of this study was to evaluate whether cisplatin sensitivity relates to patient's prognosis in oesophageal squamous cell carcinoma and to find a useful chemosensitivity molecular marker. 59 oesophageal squamous cell carcinoma (SCC) patients received cisplatin 30 mg/m2/week treatment of two to five cycles, followed by oesophagectomy. We analysed retrospectively whether the histological effect was related to patient's prognosis. Furthermore, to evaluate the relationship between the effect of preoperative cisplatin treatment and p53 and cyclin D1 expression, we investigated p53 and cyclin D1 expression in pretreatment biopsy samples using an immunohistochemical analysis and compared the results with the histological effect to cisplatin in the resected oesophagus. The cases that showed immunohistochemical p53 staining in the pretreatment biopsy samples were resistant to cisplatin (P=0.032). However, there was no relationship between cyclin D1 expression and histological effect (P=0.230). Nevertheless, combined analysis of p53 and cyclin D1 can predict histological effect (P=0.032). The prognosis of cisplatin-sensitive cases was significantly better than that of cisplatin-resistant cases (P=0.041). Cox's multivariate analysis revealed that the histological effect was an independent prognostic factor. In contrast, p53 protein accumulation and cyclin D1 were not. Histological response after neoadjuvant cisplatin treatment is a prognostic factor for oesophageal SCC and cisplatin chemotherapy may be selected according to the findings of p53 and cyclin D1 expression. Copyright (C) 2000 Elsevier Science Ltd.
KW - Cisplatin sensitivity
KW - Cyclin D1
KW - Histological response
KW - Oesophageal cancer
KW - Squamous cell carcinoma
KW - p53
UR - http://www.scopus.com/inward/record.url?scp=0034030103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034030103&partnerID=8YFLogxK
U2 - 10.1016/S0959-8049(00)00049-6
DO - 10.1016/S0959-8049(00)00049-6
M3 - Article
C2 - 10885602
AN - SCOPUS:0034030103
VL - 36
SP - 987
EP - 993
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 8
ER -
